A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School and Karolinska Institutet presents very promising results for the treatment of the cancer form multiple myeloma.
The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.
The journal Blood has published a new study on a drug candidate for multiple myeloma, a form of cancer that affects about one per cent of all tumour patients, with some 600 people a year developing the disease in Sweden. Multiple myeloma is a life-threatening disease and there is a dire medical need for new therapies, especially for the patients whose tumour cells have become resistant to the conventional drugs.
“The discovery that our substance works on multiple myeloma cells resistant to conventional therapy is very promising for the future, says Professor Stig Linder at Karolinska Institutet’s Department of Oncology-Pathology. “We’re now very hopeful that we and our colleagues at Harvard Medical School will be able to develop an effective treatment.”
The study demonstrates that the drug candidate, called VLX1570, inhibits tumour growth and prolongs survival in preclinical multiple myeloma models. The exact mechanism of action of the substance was identified earlier at Karolinska Institutet (Nature Medicine, 2011). Put simply, the tumour cells can be said to be more sensitive than normal cells to disruption to the machinery that breaks down defective proteins. When this machinery is blocked, it triggers apoptosis (programmed cell death) in the tumour cells.
“We show that the drug candidate kills multiple myeloma cells from cancer patients,” says Professor Linder. “The substance is also effective against myeloma cells that have developed a resistance to the clinically used drug bortezomib.”
Dr Dharminder Chauhan at Harvard Medical School says that the mechanism of action is very interesting as regards the development of new cancer drugs and adds, “We’re delighted to be able to study the therapeutic potential of this new drug candidate in clinical studies. We hope that the joint research we’re doing will lead to improved cancer treatments.”
The study also found that the new substance could be combined synergistically with other cancer therapies. Karolinska Institutet and Harvard Medical School are due to launch a large-scale clinical study next year in association with drug discovery company Vivolux AB (Uppsala, Sweden).
“If the study proves successful it will represent a great step forward, mainly for all cancer patients but also for the Swedish drug industry,” says Professor Linder.
The Latest on: Cancer therapies
- Lung cancer is the deadliest of all cancers, but screening could save many liveson May 9, 2024 at 6:17 am
Many medical organizations have been recommending lung cancer screening for decades for those at high risk of developing the disease. But in 2022, less than 6% of people in the U.S. eligible for ...
- Pembrolizumab/Chemo Misses on Disease-Free Survival in Endometrial Canceron May 9, 2024 at 6:00 am
The phase 3 KEYNOTE-B21 study missed its primary end point, as pembrolizumab plus chemotherapy did not improve disease-free survival in newly diagnosed, high-risk endometrial cancer.
- Matching Cancer Patients To Trials And Treatments With Triomicson May 9, 2024 at 5:00 am
Triomics has raised $15 million of funding as it moves to commercialise its AI platform for oncologists, hospitals and healthcare providers ...
- Pancreatic cancer: Symptoms, causes and treatmenton May 9, 2024 at 5:00 am
As one of the world’s leading experts in pancreatic cancer, Prof Andrew Biankin is all too familiar with the aura of dread which surrounds the disease. “There’s something about the cancer that makes ...
- Novant Health deploys high-tech robotics for lung cancer treatmenton May 9, 2024 at 4:49 am
Novant Health now has access to high-tech robotics equipment at its Agnes B. and Edward I. Weisiger Cancer Institute. That will improve diagnostics and treatment for lung cancer patients.
- Cancer: here’s the role exercise plays, from prevention to treatmenton May 9, 2024 at 4:41 am
Cancer is a complex condition, with many factors that may increase a person’s risk. But research shows exercise may actually play an important role – with a growing body of evidence showing its ...
- Merck's endometrial cancer therapy fails trialon May 9, 2024 at 4:14 am
Merck said on Thursday its therapy did not meet the main goal of disease-free survival in certain patients with endometrial cancer during a late-stage trial.
- New mRNA vaccine for deadly brain cancer triggers a strong immune responseon May 9, 2024 at 4:00 am
"These results represent an exciting advance in next generation cancer therapies that leverage mRNA, the same class of medicines used in the COVID-19 vaccines," Owen Fenton, an assistant professor of ...
- I Had Cancer. My Treatment Was Eye-Opening About Addictionon May 9, 2024 at 1:31 am
I've had two different types of cancer in two years and in both instances, I was screened, diagnosed early, and ushered into care.
- Amid Kate Middleton's Cancer Treatment, 'Positive Vibes' and 'Optimistic Mood' Prevail, Close Source Says (Exclusive)on May 8, 2024 at 1:23 pm
Kate Middleton is outside of the public eye while receiving cancer treatment, but a close source says there’s a palpable sense of "positive vibes" and an "optimistic mood." All the while, Prince ...
via Bing News
The Latest on: Multiple myeloma
- Isa-KRd Produced Durable Responses in Newly Diagnosed Multiple Myelomaon May 8, 2024 at 7:45 am
Isatuximab plus carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) produced durable responses in transplant-eligible patients with newly diagnosed multiple myeloma in a phase 2 trial.
- Persistent Sociodemographic Differences Seen in Use of AutoHCT for Multiple Myelomaon May 8, 2024 at 7:31 am
Sociodemographic differences persist in utilization of autologous hematopoietic cell transplantation (autoHCT) for multiple myeloma, according to a study published in the April issue of Clinical ...
- Verbal Workflow for Tocilizumab Orders Results in More Timely CRS Interventionon May 8, 2024 at 7:00 am
A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.
- Assessing Peripheral Neuropathy Role in Acupuncture for Managing Multiple Myelomaon May 8, 2024 at 1:04 am
The following is a summary of "Acupuncture in Multiple Myeloma Peripheral Neuropathy: A Systematic Review," published in the April 2024 issue of Pain by Lyu et al. Though a common complication of ...
- What Is The Imf Doing For The Prevention And Cure Of Multiple Myeloma? A Review By Doctorson May 7, 2024 at 2:28 pm
Expert opinion from Marcella Abunahman Pereira Specialization in Clinical Cardiology · 12 years of experience · Brazil The IMF (International Myeloma Foundation) is dedicated to improving the quality ...
- Daratumumab Therapy Effective for Newly Diagnosed High-Risk Multiple Myelomaon May 7, 2024 at 1:42 pm
Darzalex (daratumumab) is a monoclonal antibody drug currently approved for both refractory and new multiple myeloma. It’s available in intravenous and subcutaneous formulations.
- Stages of This Blood Canceron May 3, 2024 at 7:19 am
So what you want to determine is, how serious is the multiple myeloma? How extensive is it? How is it affecting other organs? There's a big spectrum with multiple myeloma and all these plasma cell ...
- Immunomodulatory Drugs in Multiple Myelomaon May 2, 2024 at 5:00 pm
This review summarizes the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic ...
- Recognizing and Managing Stress from Canceron April 30, 2024 at 10:01 am
April is National Stress Awareness Month. It reminds us to acknowledge and address stress's impact on our mental and emotional wellbeing, especially from cancer.
- Sea Colony to host annual “The Journey” Multiple Myeloma Fundraiseron April 26, 2024 at 6:52 pm
BETHANY BEACH, DE – Sea Colony Tennis Center in Bethany Beach is ramping up for their annual Multiple Myeloma 5k and tennis tournament fundraiser ‘The Journey’. The event was started in 2016 by ...
via Bing News